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Objective: To assess feasibility of overnight closed-
loop therapy in young children with type 1 diabetes
and contrast closed loop using diluted versus standard
insulin strength.
Research design and methods: Eleven children
(male 6; age range 3.75–6.96 years; glycated
hemoglobin 60 (14) mmol/mol; body mass index SD
score 1.0 (0.8); diabetes duration 2.2 (1.0) years, mean
(SD); total daily dose 12.9 (10.6, 16.5) IU/day, median
(IQR)) were studied at a clinical research facility on two
occasions. In random order, participants received closed
loop with diluted insulin aspart (CL_Dil; 20 IU/mL) or
closed loop with standard aspart (CL_Std; 100 IU/mL)
from 17:00 until 8:00 the following morning. Children
consumed an evening meal at 17:00 (44 (12) gCHO) and
an optional bedtime snack (6 (7) gCHO) identical on both
occasions. Meal insulin boluses were calculated by
standard pump bolus calculators. Basal rates on insulin
pump were adjusted every 15 min as directed by a
model-predictive-control algorithm informed by a real-
time glucose sensor values.
Results: Mean plasma glucose was 122 (24) mg/dL
during CL_Dil vs 122 (23) mg/dL during CL_Std
(p=0.993). The time spent in the target glucose range
70–145 mg/dL was 83 (70, 100)% vs 72 (54, 81)%
(p=0.328). Time above 145 mg/dL was 13 (0, 27)% vs
19 (10, 45)% (p=0.477) and time spent below 70 mg/dL
was 0.0 (0.0, 1.4)% vs 1.4 (0.0, 11.6)% (p=0.161). One
asymptomatic hypoglycemia below 63 mg/dL occurred in
one participant during CL_Dil versus six episodes in five
participants during CL_Std (p=0.09). Glucose variability
measured by CV of plasma glucose tended to be reduced
during CL_Dil (20% (13, 31) vs 32% (24, 42), p=0.075).
Conclusions: In this feasibility study, closed-loop
therapy maintained good overnight glucose control with
tendency towards reduced hypoglycemia and reduced
glucose variability using diluted insulin.
Trial registration number: clinicaltrials.gov Identifier:
NCT01557634.
Closed-loop insulin delivery is an emerging
medical innovation which aims to improve
glycemic control while reducing the risk of
hypoglycemia in type 1 diabetes.1 Closed-loop
systems combine glucose-sensing and insulin-
delivery components to modulate delivery of
insulin in a glucose-responsive fashion. The
efﬁcacy and safety of closed-loop therapy has
been demonstrated in clinical studies per-
formed in adolescents and children older than
6 years.2–5 To date, one study evaluated
closed-loop therapy in children younger than
7 years, using a proportional-integral-derivative
control approach.6
Further closed-loop research in younger chil-
dren is warranted. The incidence of type 1 dia-
betes is increasing particularly in this age
group,7–9 younger children are more prone to
hypoglycemic seizures especially overnight,10
and the developing brain appears to be more
susceptible to the adverse effects of severe hypo-
glycemia.11 A longer life-time exposure to
hyperglycemia may lead to an accentuated risk
of late microvascular and macrovascular compli-
cations. An early onset of diabetes has also
been more strongly associated with impaired
cognitive function12–15 and reduced school
achievements,16 with recent evidence of
Key messages
▪ Closed-loop insulin delivery is a promising
medical innovation for treatment of type 1
diabetes.
▪ Closed loop may be particularly beneficial for
preschool children, who are more vulnerable to
glycemic fluctuations and are at greater risk of
hypoglycemia.
▪ Safe and efficacious overnight glucose control
was attained during closed loop using diluted
and standard insulin strength, with tendency to
reduced hypoglycemia and glycemic variability
with diluted insulin.
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dysglycemia-related anatomical brain changes in young chil-
dren with type 1 diabetes.17 18 Fear of hypoglycemia is
common19 and is associated with increased psychological
burden and reduced quality of life for children and their
families,20 leading to higher than optimal glucose levels as
an attempt to prevent hypoglycemia.21 22 Glycemic control
in preschool children is often suboptimal, even when apply-
ing continuous glucose monitoring combined with insulin
pump or multiple daily injections.23 24 High insulin sensitiv-
ity as well as unpredictable food intake and physical activ-
ity25 complicate insulin dose adjustments. Infants and
young children require very small doses of insulin that chal-
lenge the accuracy of subcutaneous insulin administration
with standard concentration of 100 IU/mL.26
The purpose of our feasibility study was to evaluate
overnight closed-loop therapy with model predictive
control in young children with type 1 diabetes and to
compare closed loop using diluted versus standard
insulin strength. We hypothesized that diluted insulin
may lead to more stable glucose levels by reducing inac-
curacies in insulin delivery accentuated during the deliv-
ery of small amounts of insulin. These inaccuracies
result from electromechanical issues such as pump
plunger microjumps, insulin reservoir manufacturing
tolerances, in-line infusion set pressure variations, and
infusion set kinking.
RESEARCH DESIGN AND METHODS
An open label randomized two-period crossover study
compared overnight closed-loop insulin delivery using
diluted versus standard insulin strength. The study was
approved by the East of England—Cambridge Central
Research Ethics Committee. Participants provided assent
to the study procedures and informed consent was
signed by a parent/carer.
Subjects and study protocol
The study was conducted at the Wellcome Trust Clinical
Research Facility at Addenbrooke’s Hospital, Cambridge,
between December 2012 and November 2013. Children
aged 3–6 years were recruited from three pediatric dia-
betes clinics at Cambridge, London University College
Hospital, and Peterborough. Eligibility criteria included
type 1 diabetes (WHO criteria) for at least 6 months,
insulin pump therapy with good knowledge of insulin
dose adjustment by carers, and glycated hemoglobin
(HbA1c) below 108 mmol/mol (12%). Exclusion cri-
teria were any physical or psychological disease likely to
interfere with the normal conduct of the study and data
interpretation or current treatment with drugs likely to
interfere with glucose metabolism.
Participants attended the clinical research facility for
two overnight periods, 2–6 weeks apart, with identical
study protocol performed on both occasions. On one
occasion, participants underwent closed-loop therapy
using diluted insulin (20 IU/mL) and on the other
occasion closed loop with standard insulin strength
(100 IU/mL). The order of the interventions was
random according to a computer-generated allocation
sequence with permuted blocks placed in sealed
envelopes.
Continuous glucose monitoring was started 24–72 h
before each study visit by inserting a single glucose
sensor (Dexcom G4, Dexcom Inc, California, USA) into
the subcutaneous tissue of the upper buttocks.
Calibration followed manufacturer’s instructions using
ﬁnger-stick glucose measurements taken every 12 h on
CONTOUR XT Meter (Bayer, Leverkusen, Germany)
which was checked for accuracy by calibration ﬂuid.
On each occasion, participants were admitted at 15:30
and stayed until 8:00 the following day. On admission,
participant’s insulin pump was replaced by a study pump
(Animas 2020, Johnson & Johnson, Pennsylvania, USA)
connected to the existing infusion site. A new subcutane-
ous catheter was inserted 12–24 h before each study visit.
An intravenous cannula was placed for blood sampling
starting at 16:30. Participants consumed an evening meal
at 17:00 (44 (12) g carbohydrates) and an optional
bedtime snack (6 (7) g carbohydrates). The meals were
identical on the two occasions. Meals and carbohydrate
content were chosen by the children and their families
based on individual preferences and reﬂecting usual
practice at home. Meals were accompanied by insulin
boluses calculated using participants’ standard insulin
pump bolus calculator settings and premeal ﬁnger-stick
glucose levels.
Overnight sensor glucose levels were also recorded at
home before each study visit while children maintained
their usual exercise and eating patterns and standard
insulin pump settings were applied.
Closed loop and insulin dilution
An algorithm based on model predictive control was
used to adjust basal insulin delivery during both study
visits.27 The operation of closed-loop therapy included
manual transfer of sensor glucose data and adjustment
of pump basal insulin infusion as advised by the
computer-based algorithm at 15 min intervals, as
described previously.5 This continued from 17:00 until
8:00 the next day for 15 h.
The algorithm was initialized using participant’s
weight, total daily insulin dose, and basal insulin infu-
sion. Additionally, the algorithm was provided with
sensor glucose levels measured during a 30 min period
preceding the start of closed-loop therapy, the carbohy-
drate content of meals, and prandial insulin boluses. No
plasma glucose data were provided to the algorithm.
Further details of the closed-loop algorithm are pro-
vided elsewhere;5 we used algorithm V.0.03.26.
During closed loop, rapid acting insulin analog aspart
(Novo Nordisk, Bagsvaerd, Denmark) was infused either
at standard strength (100 IU/mL) or diluted by 0.9%
saline at 1:5 ratio resulting in an insulin concentration
of 20 IU/mL.
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Sampling and assays
Venous blood samples were obtained every 30–60 min
for the measurement of glucose and insulin concentra-
tion. Plasma was separated by centrifugation immedi-
ately. Plasma glucose levels were determined in real time
by YSI2300 STAT Plus analyzer (Yellow Springs
Instrument, Farnborough, UK) but were not used to
inform the algorithm. Plasma insulin concentration was
measured by immunochemiluminometric assay
(Invitron, Monmouth, UK; intra-assay coefﬁcient of vari-
ation (CV), 4.7%; interassay CV, 7.2–8.1%).
Statistical analysis
The primary outcome was the time with plasma glucose
levels within the target range from 70 to 145 mg/dL in
the overnight period from 21:00 until 8:00 on the follow-
ing day. Secondary outcomes included time when
glucose concentration was below 70 mg/dL (hypogly-
cemia) and glucose variability as measured by the SD of
glucose, the CV of glucose, and mean amplitude of
glucose excursions (MAGE).28 Safety measures included
hypoglycemia events (plasma glucose below 63 mg/dL)
and the low blood glucose index.29 Overnight sensor
glucose levels collected at home before study visits were
compared with sensor glucose levels measured during
closed-loop insulin delivery between 21:00 and 8:00.
Outcomes were calculated using time-weighted data by
GStat software, V.2.0 (University of Cambridge, UK).
Statistical analyses were conducted using SPSS V.21 (IBM
SPSS, Chicago, Illinois, USA). Wilcoxon signed-rank test
was used to compare non-normally distributed indices
and paired t test to compare normally distributed data.
Results are presented as median (IQR) or mean (SD)




Fourteen participants were consented and randomized.
Three participants withdrew after randomization, one at
the start of the ﬁrst study visit and two at the start of the
second visit, due to failed attempts to establish intraven-
ous sampling cannula. The study ﬂow chart is shown in
online supplementary ﬁgure S1. Eleven participants
completed the study ((male 6; age 5.07 (1.12), range
3.75–6.96 years; HbA1c 60 (14) mmol/mol; body mass
index SD score 1.0 (0.8), range −0.55, 2.11; duration of
diabetes 2.2 (1.0) years; total daily dose 12.9 (10.6, 16.5)
IU/day and 0.65 (0.59, 0.69) IU/kg/day).
Overnight glucose control
Study outcomes during the overnight period are sum-
marized in table 1. Plasma glucose, insulin delivery and
plasma insulin during closed loop with standard insulin
strength and closed loop with diluted insulin are shown
in ﬁgure 1.
Plasma glucose levels remained within the target
range of 70–145 mg/dL for 72% and 83% of the time,
respectively, when closed loop with standard insulin
strength and closed loop with diluted insulin was
applied (p=0.328; table 1). No difference was found in
the mean plasma glucose concentration (122 (23) vs
122 (24) mg/dL, p=0.993). A trend towards reduced
time spent in hypoglycemia was observed during closed
loop with diluted insulin (plasma glucose less than





diluted insulin (n=11) p Value
Primary outcome
Time in target 70–145 mg/dL (%) 72 (54, 81) 83 (70, 100) 0.328
Secondary outcomes
Mean glucose (mg/dL) 122 (23) 122 (24) 0.993
Time in target 70–180 mg/dL (%) 85 (72, 97) 98 (79, 100) 0.328
Hypoglycemia
Less than 70 mg/dL (%) 1.4 (0.0, 11.6) 0.0 (0.0, 1.4) 0.161
Less than 63 mg/dL (%) 0.0 (0.0, 7.9) 0.0 (0.0, 0.0) 0.249
Low blood glucose index (unitless) 2.0 (0.6, 2.2) 0.7 (0.2, 1.0) 0.050
Hyperglycemia
Greater than 145 mg/dL (%) 18.8 (9.5, 44.9) 13.0 (0.0, 26.9) 0.477
Greater than 180 mg/dL (%) 5.1 (0.0, 26.8) 0.0 (0.0, 15.3) 0.953
Glucose variability
SD of glucose (mg/dL) 35 (26, 53) 26 (14, 39) 0.091
CV of glucose (%) 32 (24, 42) 20 (13, 31) 0.075
MAGE (mg/dL) 80 (0, 112) 32 (0, 63) 0.074
Insulin infusion (U/h) 0.2 (0.2, 0.3) 0.2 (0.1, 0.3) 0.328
Insulin concentration (pmol/L) 141 (35, 262) 112 (50, 144) 0.213
Data are mean (SD) or median (IQR).
Outcomes calculated between 21:00 and 8:00 and based on plasma glucose levels.
CV, coefficient of variation; MAGE, mean amplitude of glucose excursions.
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70 mg/dL, p=0.161). A reduced low blood glucose index
supported this observation (p=0.050). Sensor-based
assessment indicated signiﬁcant reduction of time below
63 mg/dL (p=0.028) and a reduced low blood glucose
index (p=0.026; see online supplementary table S1).
Insulin infusion rates were not different during the
two interventions (0.2 (0.2, 0.3) vs 0.2 (0.1, 0.3) U/h,
p=0.328) and resulted in similar plasma insulin levels
(p=0.213).
Hypoglycemia and glucose variability
No episode of hypoglycemia requiring treatment
occurred during either intervention. One asymptomatic
episode of hypoglycemia below 63 mg/dL as measured
by plasma glucose occurred in one participant during
closed loop with diluted insulin as compared with six
episodes in ﬁve participants during closed loop with
standard insulin (p=0.09). All these episodes resolved
with no carbohydrate intake within 15–45 min.
All measurements of glycemic variability showed a ten-
dency towards reduced variability during closed loop
with diluted insulin, although these differences were not
statistically signiﬁcant (table 1).
Sensor accuracy
The median relative absolute difference of Dexcom G4
continuous glucose monitor was 11.6% (6.6, 18.8). The
Clarke error grid analysis30 (see online supplementary
ﬁgure S2) provided 98.6% of the values were in zone
A+B, 0% in zone C, 1.4% in zone D, and 0% in zone E.
Glycemic control at home
Comparison between sensor glucose during conven-
tional insulin pump therapy at home settings and
closed-loop therapy using standard and diluted insulin is
summarized in table 2.
CONCLUSIONS
We show that closed-loop therapy using a model predict-
ive control approach can be safely and effectively
applied for overnight glucose control in young children
aged 3–6 years with type 1 diabetes. Plasma glucose
levels were maintained between 70 and 145 mg/dL for
72% and 83% of the time using closed loop with stand-
ard and diluted insulin, respectively, and mean glucose
was 122 mg/dL during both interventions. No episodes
of hypoglycemia requiring treatment occurred over 22
study nights.
The present study builds on previous observations in
older children and adolescents about beneﬁts of over-
night closed-loop therapy using the model predictive
control at the clinical research facility5 and in the
unsupervised home settings.31 In the present study, we
document good glucose control in younger children,
who may greatly beneﬁt from closed-loop therapy.
Similar results in terms of proportion of time spent in
the target range and in hypoglycemia were obtained in
this age group as compared with older children and ado-
lescents.32 33 The daily management of diabetes in a
young child is complicated by ampliﬁed responsiveness
to insulin, increased risk of nocturnal hypoglycemia,
high glucose variability and unpredictability of food
intake and physical activity. While the avoidance of hypo-
glycemia is a crucial concern, chronic hyperglycemia
and glucose variability have been suggested to be
equally detrimental for brain development and may
affect cognition.18 Children younger than 4 years were
Figure 1 Plasma glucose (A), insulin infusion rates (B), and
plasma insulin (C) are shown for closed loop with standard
insulin strength (grey line) and closed loop with diluted insulin
(black line; median (IQR)). Horizontal dashed lines illustrate
the target glucose levels between 70 and 145 mg/dL. The
vertical dashed line indicates when closed loop started and
the evening meal was consumed.
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found to spend more than 4 h/day with glucose levels
greater than 250 mg/dL when continuous glucose moni-
toring was applied.25 Similarly, no evidence of improved
glycemic control with insulin pump therapy has been
demonstrated in younger children34 possibly owing to
the small number of studies targeting this age group.
Closed-loop insulin delivery using a proportional-integral-
derivative approach in children younger than 7 years was
investigated by Dauber et al6 documenting reduced over-
night exposure to hyperglycemia as compared with conven-
tional insulin pump therapy. Although closed loop was not
associated with improvements in the time spent in target or
with reduced frequency of hypoglycemia, the study was the
ﬁrst to evaluate closed-loop therapy in younger children.
The novelty of our study is the use of diluted insulin
to enhance the accuracy of delivery of small insulin
doses. When compared with standard insulin strength,
diluted insulin during closed-loop therapy tended to
reduce the risk of hypoglycemia as evaluated by the low
blood glucose index (p=0.050) and time spent in hypo-
glycemia less than 70 mg/dL (p=0.161). Sensor-based
assessment of hypoglycemia showed a signiﬁcant reduc-
tion in the time spent in hypoglycemia below 63 mg/dL
(p=0.028) and the low blood glucose index (p=0.026)
suggesting that sensor errors attenuated the differences
when outcomes were measured by reference plasma
glucose.35 Sensor accuracy data are sparse in this young
age group. Episodes of asymptomatic self-resolving mild
hypoglycemia tended to be lower during closed loop
using diluted insulin (p=0.09).
We observed a tendency towards reduced glycemic
variability during closed loop with diluted insulin. The
median CV of glucose was 20% during closed loop with
diluted insulin versus 32% when standard strength
insulin was used (p=0.075). Other measures of glucose
variability conﬁrmed this trend (table 1). These CVs are
lower than those reported by Tsalikian et al,23 who
observed a median CV of glucose between 35% and
45% in children younger than 4 years using continuous
glucose monitoring, and by Slover et al36 during sensor-
augmented pump therapy. Glycemic variability has been
inconsistently associated with the risk of vascular compli-
cations in diabetes.37 In younger children, increased gly-
cemic variability along with chronic exposure to
hyperglycemia have been recently found to be associated
with changes in the brain’s white matter.17
We chose a dilution so that the volume of insulin
scales from 10 U/day of standard strength insulin to
50 U/day of diluted insulin, a common amount applic-
able in adults. The latter converts to basal insulin deliv-
ery of about 1 U/h, a rate at which accuracy of insulin
pump is assessed and optimized. A greater dilution may
further increase accuracy by limiting the effect of micro-
bubbles and to overcome tissue pressure build-up but
greater dilutions may be an issue in children requiring a
larger amount of insulin due to pain at the cannula site.
The strength of the study is the randomized study
design. The lack of control therapy is a limitation moti-
vated by practical reasons to reduce burden for young
participants and taking into account existing evidence of
suboptimal glycemic control with frequent hypergly-
cemic excursions23 24 and undetected hypoglycemia38 in
younger children on standard therapy. We carried out a
post hoc analysis and although detailed information on
Table 2 Comparison between glucose control based on sensor glucose during standard insulin pump therapy at home the
night before the study visits and during closed loop with diluted and standard insulin at the clinical research facility
Outcome
Insulin pump






Time in target 70–145 mg/dL (%) 32 (30, 59) 71 (51, 78) 78 (68, 94)
Secondary outcomes
Mean glucose (mg/dL) 151 (71) 126 (30) 121 (22)
Time in target 70–180 mg/dL (%) 59 (44, 76) 82 (61, 91) 89 (77, 95)
Hypoglycemia
Less than 70 mg/dL (%) 12 (0, 23) 8.0 (2.4, 17.7) 1.8 (0.0, 4.8)
Less than 63 mg/dL (%) 4.7 (0.0, 11.6) 4.1 (0.8, 11.4) 0.0 (0.0, 0.0)
Low blood glucose index (unitless) 1.7 (0.1, 5.4) 1.7 (1.2, 3.3) 1.0 (0.7, 1.4)
Hyperglycemia
Greater than 145 mg/dL (%) 52 (15, 69) 15 (12, 32) 17 (2, 32)
Greater than 180 mg/dL (%) 22 (4, 35) 2 (0, 21) 9 (0, 17)
Glucose variability
SD of glucose (mg/dL) 42 (30, 51) 33 (27, 57) 35 (18, 44)
CV of glucose (%) 27 (23, 44) 32 (27, 46) 30 (17, 34)
MAGE (mg/dL) 67 (41, 107) 100 (56, 141) 77 (26, 102)
Insulin infusion (U/h) 0.2 (0.1, 0.2) 0.2 (0.2, 0.3) 0.2 (0.1, 0.3)
Data are mean (SD) or median (IQR).
Outcomes calculated between 21:00 and 8:00 and based on sensor glucose.
CV, coefficient of variation; MAGE, mean amplitude of glucose excursions.
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children’s schedule at home, that is, the time of evening
meal/bedtime the night before the study was not avail-
able, our data showed that glucose control during con-
ventional pump therapy in the home settings appeared
inferior to that obtained during closed-loop therapy
using standard as well as diluted insulin (table 2).
In conclusion, the present exploratory study suggests
that closed-loop insulin delivery using the model predict-
ive control approach is safe and efﬁcacious to maintain
overnight glycemic control in young children with type 1
diabetes. Closed-loop therapy using insulin dilution
tended to reduce hypoglycemia and glycemic variability
as compared to closed loop with standard insulin
strength. The use of insulin dilution to enhance accur-
acy of insulin delivery may be explored in larger studies.
Difﬁculties related to the use of insulin dilution, that is,
the need to prepare diluted insulin every 7–14 days and
the availability of speciﬁc software on insulin pumps to
avoid dosing errors, may also need to be taken into
account. Our ﬁndings support research into closed-loop
therapy in preschool children, who may greatly beneﬁt
from this novel therapeutic approach.
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